Android app on Google Play

Thoratec (THOR), Heartware (HTWR) Stocks in Focus Following NEJM Study

November 29, 2013 9:07 AM EST Send to a Friend
Get Alerts THOR Hot Sheet
Price: $26.28 --0%

Rating Summary:
    12 Buy, 15 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 12 | Down: 11 | New: 37
Trade THOR Now!
Join SI Premium – FREE
Thoratec (NASDAQ: THOR) stock was pressured early on Friday after a NEJM study. While the study was concerning, it is likely inconclusive, thinks analyst Danielle Antalffy of Leerink Swann. He expects Thoratec and Heartware International Inc. (Nasdaq: HTWR) to react to the news.

"Wednesday after market close, NEJM published a 3- center study highlighting a meaningful increase in thrombus formation in HeartMate II implants performed after March 2011 -- to 8.4% at 3 months post-implant from 2.2% in the period of 2004- March 2011. This high thrombus rate compares to published HeartMate II clinical trials demonstrating a 3-month thrombus rate in the 2%-4% range. While THOR shares could trade down temporarily in reaction to the NEJM article, we continue to believe mid-teens LVAD market growth is sustainable over the next few years, as the study sample is still relatively small and centers are unlikely to dramatically adjust clinical practice on this study alone," said Antalffy.

"Conversely, HTWR shares could react positively to this study as it seemingly mitigates the concerns around high thrombus rates with LVADs and evens the playing field from a competitive perspective," he added.

Leerink Swann has an Outperform rating on Thoratec with a price target of $45.00

For an analyst ratings summary and ratings history on Thoratec (NASDAQ: THOR) click here. For more ratings news on Thoratec click here.

Shares of Thoratec closed at $42.12 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Hot Comments, Trader Talk

Add Your Comment